𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bcl-xL confers multi-drug resistance in several squamous cell carcinoma cell lines

✍ Scribed by T. Noutomi; H. Chiba; M. Itoh; H. Toyota; J. Mizuguchi

Book ID
114393720
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
258 KB
Volume
38
Category
Article
ISSN
1368-8375

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Bcl-xL and Bcl-2 expression in squamous
Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
✍ John C. Pena; Craig B. Thompson; Wendy Recant; Everett E. Vokes; Charles M. Rudi πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 234 KB πŸ‘ 2 views

## Background: Inhibition of apoptosis, or programmed cell death, may be critical both in the development of cancer and in determining response to therapy. the authors examined the expression of two related apoptotic inhibitors, bcl-2 and bcl-xl, in pretreatment biopsies from a series of 42 patient

Bcl-xL inhibits p53- but not apoptin-ind
Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line
✍ Remilio A.L. Schoop; Klaas Kooistra; Robert J. Baatenburg de Jong; Mathieu H.M. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 174 KB πŸ‘ 1 views

Nonfunctional p53 and especially upregulation of Bcl-x(L) result in advanced disease and poor prognosis of patients suffering head and neck squamous cell carcinoma (HNSCC). Aberrancies of Bcl-x(L) and/or p53 in HNSCC lead to inability of anticancer drugs to induce apoptosis. Bcl-x(L) and/or mutated